Table 2.
Treatment details of CIDP patients without and with DM.
| CIDP without DM and CIDP with DM patients (N = 134) | P value | ||
|---|---|---|---|
|
| |||
| CIDP without DM (n = 67) | CIDP with DM (n = 67) | ||
| Response to treatment (n = 100) | 0.71 | ||
| Non-responders, n (%) | 29 (45) | 17 (49) | |
| Responders, n (%) | 36 (55) | 18 (51) | |
| Treatment provided, n (%) | 62 (93) | 36 (57) | <0.0001* |
| IVIg, n (%) | 58 (87) | 33 (52) | <0.0001* |
| Prednisone, n (%) | 44 (67) | 12 (19) | <0.0001* |
| PE, n (%) | 10 (15) | 3 (5) | 0.040 |
| Azathioprine, n (%) | 36 (55) | 7 (11) | <0.0001* |
| Mycophenolate mofetil, n (%) | 9 (14) | 6 (10) | 0.460 |
| Loading dose IVIg (2 g/kg) | 1.86 ± 0.4 | 1.97 ± 0.4 | 0.230 |
| IVIg treatments, n (range) | 22.4 ± 39.6 (1–200) | 7.02 ± 12.2 (0–60) | 0.020 |
| Response to IVIg treatment, n (%) | 46 (84) | 18 (56) | 0.006 |
| PE treatments, n (range) | 1.4 ± 0.9 (1–3) | 4.7 ± 0.6 (4–5) | 0.0002* |
| Response to PE treatment, n (%) | 9 (82) | 2 (67) | 0.590 |
| Clinical status (n = 100) | 0.130 | ||
| Worse, n (%) | 16 (25) | 4 (11) | |
| No change, n (%) | 13 (20) | 13 (37) | |
| Stabilized, n (%) | 21 (32) | 8 (23) | |
| Improved, n (%) | 15 (23) | 10 (29) | |
| NCS after treatment (n = 93) | 0.850 | ||
| Worse, n (%) | 8 (14) | 6 (18) | |
| Stable, n (%) | 48 (81) | 26 (76) | |
| Improved, n (%) | 3 (5) | 2 (6) | |
Table adapted from Dunnigan SK et al. PLoS One. 2014;9(2):e89344 with permission. Data are mean ± SD unless otherwise indicated. Differences in categorical variables were assessed in three-group comparisons using the χ2-test, while differences in continuous variables were assessed using the analysis of variance.
**
Bonferroni corrected P value for significance = 0.003. CIDP, chronic immune demyelinating polyneuropathy; DM, diabetes mellitus; IVIg, intravenous immunoglobulin; PE, plasma exchange; NCS, nerve conduction study; SD, standard deviation.